Stay updated on Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe site footer revision label changed from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check8 days agoChange DetectedThe record for the pembrolizumab study in anaplastic or undifferentiated thyroid cancer is displayed with its trial details, results, eligibility criteria, and study documents.SummaryDifference44%

- Check15 days agoChange DetectedThe footer’s ClinicalTrials.gov revision number changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check29 days agoChange DetectedA notice about NIH’s terminology transition was added above the 403 error page, and the footer revision label changed from v3.7.1 to v3.7.2.SummaryDifference1%

- Check43 days agoChange DetectedThe site revision displayed in the footer changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check57 days agoChange DetectedThe study record page now renders a 403 Forbidden error, replacing the expected study details with an access-restricted page. This indicates a permissions issue rather than a change to the study data.SummaryDifference17%

Stay in the know with updates to Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Clinical Trial page.